Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer

BMC Cancer

Table 2 Patient characteristics according to breast pathological complete response

	Non-pCR (n = 155)	pCR (n = 198)	All (n = 353)	P-value
Age (years), mean ± SD	49.38 ± 10.19	48.53 ± 9.91	48.94 ± 10.04	0.295
Tumor stage
cT1-2	100	136	236	0.493
cT3-4	55	62	117	0.493
Lymph node status
Negative	23	35	58	0.475
Positive	132	163	295	0.475
ER status
Negative	63	137	200	< 0.001
Positive	92	61	153	< 0.001
PR status
Negative	104	176	280	< 0.001
Positive	51	22	73	< 0.001
Histological Grade
I-II	94	95	189
III	61	103	164	0.018
Ki-67 index
< 30%	20	10	30	0.009
≥ 30%	135	188	323	0.009
HER2 status
2 +	42	14	56	< 0.001
3 +	113	184	297	< 0.001
IMPC
with	20	2	22	< 0.001
without	135	196	331	< 0.001
Chemotherapy regimens
THP*4	49	54	103	0.332
TCbHP*6	87	126	213
AC4-THP4	19	18	37

ISSN: 1471-2407